Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

PURPOSE: We evaluated efficacy and tolerability of the combination of ofatumumab and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), and explored whether immune system characteristics could influence the response to treatment. EXPERIMENTAL DESIGN: Thirty-four pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Vitale, Candida, Falchi, Lorenzo, ten Hacken, Elisa, Gao, Hui, Shaim, Hila, Van Roosbroeck, Katrien, Calin, George, O'Brien, Susan, Faderl, Stefan, Wang, Xuemei, Wierda, William G., Rezvani, Katayoun, Reuben, James M., Burger, Jan A., Keating, Michael J., Ferrajoli, Alessandra
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5118034/
https://ncbi.nlm.nih.gov/pubmed/26733610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2476
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars